5 completed. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 2 | Completed 2 |
Follow Innocrin Pharmaceutical: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) Seviteronel - Cancer of the Breast, Breast Cancer | Phase 1 / Phase 2 | Completed | Innocrin Pharmaceutical | 175 | 2015-08-01 | 2019-02-01 |
| Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. Seviteronel: given orally once daily in 28-day cycles - Prostate Cancer | Phase 2 | Completed | Innocrin Pharmaceutical | 197 | 2015-05-01 | 2019-02-01 |
| A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer VT-464: given orally once daily in 28 day cycles - Castration-resistant Prostate Cancer, CRPC | Phase 1 / Phase 2 | Completed | Innocrin Pharmaceutical | 21 | 2014-06-01 | 2019-02-01 |
| Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles - Prostate Cancer | Phase 2 | Completed | Innocrin Pharmaceutical | 17 | 2014-04-01 | 2018-05-07 |
| A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Seviteronel: given orally once daily in 28 day cycles - Castration-resistant Prostate Cancer, CRPC | Phase 2 | Completed | Innocrin Pharmaceutical | 200 | 2011-12-01 | 2019-02-01 |
Prostatic Neoplasms (3) · Neoplasm Metastasis (2) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Triple Negative Breast Neoplasms (1)
seviteronel (3) · VT-464 (2)
United States (5) · Greece (1) · Switzerland (1) · United Kingdom (1)
Joel Eisner (1) · Victoria Brown, BS (1)